Dingell subcommittee's interest in the generic firm is focused on the company's conjugated estrogens ANDA and the events surrounding FDA's policy change on bioequivalence requirements for generic versions of Wyeth-Ayerst's Premarin, Able says. Attachments to a March 14 letter from Rep. Dingell (D-Mich.) and Rep. Bliley (R-Va.) to HHS Secretary Sullivan on the investigation of FDA's generic division list Able as one of six companies for which Dingell is seeking compliance records and AF jackets from FDA ("The Pink Sheet" March 27, p. 7). Able says it is not involved in the ongoing criminal investigation by a Baltimore grand jury.
You may also be interested in...
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.